Improving Host Factors in Patients With Monoclonal Gammopathies and Other Hematologic Disorders

Summary

This clinical trial investigates the effect of non-chemotherapeutic interventions in patients with multiple myeloma or MDS. Non-chemotherapeutic interventions such as physical activity and nutritional interventions (e.g., modifications in diet) have been shown to positively affect the immune system and improve overall quality of life. Another purpose of this study is for researchers to learn how the addition of a beta-blocker (propranolol) to the standard treatment regimen in patients with newly diagnosed multiple myeloma affects immune response and quality of life. A study from the Mayo Clinic looked at multiple myeloma patients who were on a beta-blocker while undergoing chemotherapy and found that the use of a beta-blocker resulted in improved patient survival outcomes. Non-chemotherapeutic treatment options may help decrease symptoms and improve quality of life for patients with multiple myeloma.

Description

Eligibility

Age range

18+ years

Sex

All

Healthy volunteers

No

Interventions

• Behavioral
  Behavioral Intervention

  Wear a FitBit device and receive prompts for 6 months

• Drug
  Beta-Adrenergic Antagonist

  Receive beta-blocker regimen as per SOC

• Drug
  Propranolol

  Given PO

• Other
  Quality-of-Life Assessment

  Ancillary studies

• Other
  Questionnaire Administration

  Ancillary studies

• Other
  Resistance Training

  Undergo strength training for 6 months

• Other
  Short-Term Fasting

Location